Friday, July 10, 2026

pharma · Asthma · Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A

Chiesi Farmaceutici S.p.A is a pharma organization headquartered in Parma, IT. Primary therapeutic focus areas include Asthma, Idiopathic pulmonary fibrosis (IPF), Mild to moderate asthma, Pulmonary fibrosis, Chronic obs

Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT HQ
6,080 Employees
EMA registrant Type
Company details
Status
Public
HQ
Via Paradigna, 131, Parma, Emilia-Romagna 43122, IT
Employees
6,080
Programs
20
Drugs
38
Patents
0
Clinical program

CHF6001 DPI

Phase 2 · small molecule · Asthma

CHF6001 DPI for Asthma is a Phase 2 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

← All Chiesi Farmaceutici S.p.A projects Phase 2 small molecule active

Internal code CLI-06001AC1-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chiesi Farmaceutici S.p.A
Phase
Phase 2
Modality
small_molecule
Indication
Asthma
Status
active
Trials
1

Clinical trials